Side-by-side · Research reference
GHRP-2vsLivagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED15/42 cited
BAnimal-StrongHUMAN-REVIEWED20/32 cited
GHRP-2
Hexapeptide GHRP · Phase 2 (clinical diagnostic)
SQ · Multiple sites · 1–3×/day
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
01Mechanism of Action
Parameter
GHRP-2
Livagen
Primary target
Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
Downstream effect
Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Feedback intact?
Yes, with somatostatin feedback active
—
Origin
Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-2
Livagen
Frequency
1–3× per day
—
Lower / starter dose
50 mcg per dose
—
Evidence basis
Phase 2 + clinical diagnostic useBowers 1990
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Duration
8–12 weeks on / 4 off (anecdotal)
—
Reconstitution
Bacteriostatic water
—
Timing
Pre-sleep + fasted preferred
—
Animal dose (oral)
—
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
Duration (experimental)
—
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
Route
—
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
Human data
—
None in provided literature
04Side Effects & Safety
Parameter
GHRP-2
Livagen
Prolactin elevation
Mild but measurable
—
Hunger
Strong appetite increase
—
Injection site reaction
Mild erythema
—
IGF-1 elevation
Strong; monitor with chronic high-dose use
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
—
Reported adverse effects
—
None documented in animal studies
Human safety data
—
No human trials in provided literature
Absolute Contraindications
GHRP-2
- ·Active malignancy
- ·Pregnancy / breastfeeding
Livagen
—Relative Contraindications
GHRP-2
- ·Untreated diabetes
Livagen
—05Administration Protocol
Parameter
GHRP-2
Livagen
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
2. Injection site
SQ — abdomen or thigh. Rotate sites.
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
3. Timing
Pre-sleep + fasted preferred.
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
—
5. Needle
29–31G, 4–8 mm insulin syringe.
—
06Stack Synergy
GHRP-2
+ CJC-1295 (no DAC)
StrongGHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.
- GHRP-2
- 100–200 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- High-amplitude GH pulse, body composition
Livagen
— no documented stacks